Data completeness
0/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NYSTAFORM is a topical ointment combining clioquinol and nystatin for the treatment of fungal and bacterial skin infections. The combination leverages nystatin's antifungal activity against Candida species and clioquinol's broad-spectrum antimicrobial properties. This fixed-dose combination is indicated for dermatological conditions where dual antimicrobial coverage is therapeutically beneficial.
Pre-Launch
Pre-launch status indicates a small, focused team preparing for market entry with growth potential dependent on regulatory approval and market adoption.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NYSTAFORM represents an early-stage career opportunity in a pre-launch dermatology product with R-Pharm US. Entry roles will focus on regulatory clearance, market preparation, and launch execution, offering exposure to pharmaceutical commercialization in a niche topical segment.
Brand ManagerRegulatory Affairs Specialist
Worked on NYSTAFORM at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.